vitronectin antagonists (sanofi-aventis)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namevitronectin antagonists (sanofi-aventis)
Drug Alias Namevitronectin antagonists (Aventis)vitronectin antagonists (sanofi-aventis/Genentech)vitronectin antagonists (Hoechst Marion Roussel)V-0005V-0223 +[8] 
ClassificationSmall molecules
Mechanisms of ActionAngiogenesis inhibitorsPlatelet aggregation inhibitorsIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsAngiogenesis disorderWounds and InjuriesImmune System Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHoechst Marion Roussel Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAventisHoechst Marion Roussel Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsAngiogenesis disorderWounds and InjuriesImmune System Diseases +[7] 

Other Information

ATC CodeN/A
Related LinksN/A